Secondary acute promyelocytic leukemia after treatment with etoposide for langerhans cell histiocytosis (LCH)

✍ Scribed by Lopes, Luiz Fernando; de Camargo, Beatriz

• Publisher: John Wiley and Sons
• Year: 1999
• Tongue: English
• Weight: 24 KB
• Volume: 32
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/(sici)1096-911x(199904)32:4<315::aid-mpo17>3.0.co;2-6

✦ Synopsis

To the Editor: We here describe a 3-year-old-boy who was treated for LCH using vinblastine, etoposide and prednisone according to the International Langerhans Cell Histiocytosis Study I. The patient was admitted in March 1993 with multiple bone lesions, diabetes insipidus and biopsy confirmed LCH. He was treated with vinblastine and prednisone for 6 months. In October 1995 he relapsed with multiple bone lesions and severe pain. Treatment was resumed with weekly etoposide and prednisone for 3 months and then etoposide every 3 weeks for 3 more months. His treatment was irregular because of social-economic family problems. From March 1996 to October 1997 he was in remission without treatment when he was admitted to our unit with fever and sinusitis. Laboratory investigations showed a leukocyte count of 4.800 mm 3 with 63% of blasts. A bone marrow aspirate confirmed a French-American-British (FAB) M3 with CD33 89% positive, CD13 90% positive, MPO 70% positive, CD15 60% positive, CD19 no markers. Cytogenetic studies of the bone marrow showed *Our patients received only 1560 mg/m 2 of etoposide and that, irregularly.